Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

IGF-1 LR3 News 2026: Research-Grade Peptide Comparison

| Peptide Analog | Primary Receptor Target | Half-Life (In Vitro) | Ambient Stability Post-Reconstitution | Endotoxin Risk (Unregistered Suppliers) | IRS Pathway Selectivity | Professional Assessment ||—|—|—|—|—|—|| IGF-1 LR3 | IGF-1R (primary), IR (>100 ng/mL

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • | Peptide Analog | Primary Receptor Target | Half-Life (In Vitro) | Ambient Stability Post-Reconstitution | Endotoxin Risk (Unregistered Suppliers) | IRS Pathway Selectivity | Professional Assessment ||—|—|—|—|—|—|| IGF-1 LR3 | IGF-1R (primary), IR (>100 ng/mL) | 20–30 hours | 72 hours before 18% affinity loss (25°C) | High (2 contamination incidents in 2026) | IRS-2 activation at high dose—metabolic crosstalk | Best for proliferation studies at 10–100 ng/mL; requires cold storage and registered supplier || Native IGF-1 | IGF-1R | 10 minutes (IGFBP-sensitive) | <24 hours (rapid oxidation) | Moderate | IRS-1 selective at physiological concentrations | Limited research utility due to IGFBP sequestration and short half-life || Des(1-3) IGF-1 | IGF-1R (high affinity) | 30–60 minutes | 48 hours (25°C) | Moderate | IRS-1 dominant | Preferred for short-duration signaling studies; less dual-receptor risk || Insulin (recombinant human) | IR (exclusive) | 4–6 minutes | 7 days (4°C, neutral pH) |
  • IGF-1 LR3 remains the most widely used IGF-1 analog for in vitro proliferation studies due to its extended half-life and resistance to IGF-binding protein interference, but the 2026 stability and receptor binding data introduced constraints researchers must now design around: cold storage is non-negotiable beyond 72 hours, supplier vetting is a data integrity requirement rather than a procurement preference, and dose selection must account for insulin receptor activation at concentrations above 100 ng/mL. The analog's utility hasn't diminished—the precision required to use it correctly has simply increased.